Se­r­i­al biotech en­tre­pre­neur Michael Gilman takes his key to the $100M-plus club and goes all-in on drug­ging RNA

Sci­en­tist and biotech en­tre­pre­neur Michael Gilman is join­ing the $100 mil­lion-plus club with his start­up Ar­rakis. And he’s all-in as the de­vel­op­er — one of the more promi­nent play­ers in a pack of biotechs look­ing to use small mol­e­cules to drug RNA — sets out to tran­si­tion from plat­form build­ing to pipeline con­struc­tion.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER